GLP-1 Medications and Immune Function: What Research Shows About Infection Outcomes

*This article is for informational and educational purposes only. It is not medical advice. Compounded semaglutide and tirzepatide are not FDA-approved. Clinical research cited here involved FDA-approved GLP-1 formulations or observational studies of patients using GLP-1 receptor agonists. Individual results vary. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

Most conversations about GLP-1 medications start with weight. That makes sense. Significant weight loss changes a lot about how the body functions, including blood sugar regulation, blood pressure, cardiovascular risk, and joint health.

But a growing body of research is asking a less obvious question: does the underlying biology of GLP-1 receptor agonists also affect how the immune system works?

The early evidence is intriguing. People using GLP-1 medications appear to have better outcomes from some serious infections. Researchers are finding GLP-1 receptors expressed on immune cells throughout the body. And the anti-inflammatory effects of this drug class are increasingly understood as something broader than simply treating metabolic disease.

Here is what the current science shows, and what it does not yet prove.

---

Why Obesity Puts the Immune System at a Disadvantage

Before looking at GLP-1 medications specifically, it helps to understand the immune burden that excess weight creates.

Adipose tissue is not just a passive energy reservoir. Fat cells, particularly the visceral fat stored deep around the abdominal organs, are metabolically active. They produce pro-inflammatory signaling molecules called adipokines and cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and leptin. In people with obesity, this steady low-level inflammatory output creates a state of chronic systemic inflammation.

That chronic inflammation interferes with immune function in several ways. It can exhaust immune cells that would otherwise respond to acute threats, divert immune resources toward managing ongoing inflammation, and disrupt the balance between the innate and adaptive immune branches.

A 2024 review published in *Immunity and Ageing* (Valentino et al., PMID 39616399) examined how obesity interacts with immune aging. The authors found that excess adipose tissue accelerates immunosenescence, the gradual deterioration of immune function associated with aging, through mechanisms including elevated autoantibody production and dysregulated immune signaling. This immune aging effect means that people with obesity may have less functional immune reserve to call on when they encounter a serious infection.

The downstream consequences are well-documented. Research has established obesity as an independent risk factor for severe outcomes from respiratory infections, including influenza and COVID-19. A 2021 study published in *Diabetes Care* (Longmore et al., PMID 33858854) found that both overweight/obesity and diabetes were independent risk factors for in-hospital severity of COVID-19 in a large cohort analysis. Critically, the study found these effects were non-additive: having both conditions did not simply double the risk, but the independent contribution of excess weight to severe COVID-19 outcomes was confirmed regardless of diabetes status.

This is the immune landscape that GLP-1 receptor agonists work within.

---

GLP-1 Receptors in the Immune System

GLP-1 was first identified for its role in blood sugar regulation. When you eat, the gut releases GLP-1, which signals the pancreas to produce insulin. GLP-1 receptor agonists, like semaglutide and tirzepatide, mimic this hormone, reducing blood sugar, slowing gastric emptying, and reducing appetite.

But GLP-1 receptors are expressed far beyond the pancreas. They are found in the heart, kidneys, brain, gut, and, importantly for this discussion, on immune cells throughout the body.

Macrophages, T cells, and dendritic cells have all been shown to express GLP-1 receptors. When GLP-1 receptor agonists activate these receptors, they appear to shift macrophage activity away from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype, inhibit NF-kB signaling (a master regulator of the inflammatory response), and reduce the production of pro-inflammatory cytokines like TNF-alpha and IL-6.

A 2026 review published in *Canadian Journal of Physiology and Pharmacology* (Bajic et al., PMID 42132521) synthesized the evidence on anti-inflammatory mechanisms of GLP-1 receptor agonists in cardiovascular disease. The authors detailed how GLP-1 receptor activation directly modulates immune cell function and reduces systemic inflammatory burden through pathways independent of weight loss or blood sugar improvement. This is important because it suggests a direct immunomodulatory role for GLP-1 receptor agonists, not just an indirect benefit from better metabolic control.

---

What the Research Shows: COVID-19 Outcomes

The COVID-19 pandemic generated an enormous body of observational data, and some of the most striking findings involve GLP-1 receptor agonist users.

A 2025 cohort study published in *BMJ Open Diabetes Research and Care* (Thompson et al., PMID 40780839) examined the association between GLP-1 receptor agonist use and COVID-19 infection and adverse outcomes in a large real-world population. The study compared outcomes across medication classes and found meaningful signals suggesting that GLP-1 receptor agonist users experienced different COVID-19 trajectories compared to patients on other diabetes medications.

A 2024 meta-analysis and systematic review published in *Therapeutic Innovation and Regulatory Science* (Song et al., PMID 38683419) synthesized data from multiple observational studies examining how different antihyperglycemic medications affected COVID-19 outcomes. The analysis found that GLP-1 receptor agonists were among the medication classes associated with more favorable outcomes, consistent with the hypothesis that the anti-inflammatory and metabolic effects of this drug class confer some protection against severe respiratory illness.

It is important to note what this research does and does not establish. These are observational studies. Patients who were prescribed GLP-1 medications may differ from other patients in ways that independently affect COVID-19 risk. GLP-1 receptor agonists are not a treatment for COVID-19 and should not be understood as preventive therapy for any specific infection. What this research suggests is that the broader metabolic and anti-inflammatory effects of this medication class may reduce some of the immune vulnerabilities associated with obesity and metabolic disease.

---

Sepsis and Critical Illness

Research interest in GLP-1 receptor agonists extends beyond COVID-19 into the broader territory of critical illness and sepsis.

Sepsis is the body's dysregulated response to infection, representing a leading cause of hospital mortality. The immunology of sepsis involves a complex interplay between excessive initial inflammation and subsequent immune suppression. Both phases represent potential therapeutic targets.

A 2025 review published in *Cardiology in Review* (Tomy et al., PMID 40745623) examined the emerging evidence for GLP-1 receptor agonists in sepsis management. The authors reviewed both preclinical and early clinical data suggesting that GLP-1 receptor agonists may modulate sepsis-related inflammation, reduce organ damage markers, and potentially improve survival outcomes in critical illness. The mechanisms proposed include direct anti-inflammatory action at GLP-1 receptors expressed on immune and cardiac cells, as well as the beneficial metabolic effects on blood glucose control that are independently known to affect sepsis outcomes.

The authors were careful to note that large randomized controlled trials specifically designed to test GLP-1 receptor agonists in sepsis are not yet available, and that the current evidence base consists largely of preclinical models and observational data. This is an active area of research, not an established therapeutic application.

---

Does Weight Loss Itself Improve Immune Function?

It is worth separating two mechanisms: the direct immunomodulatory effects of GLP-1 receptor activation described above, and the immune benefits that come from weight loss itself.

Both are likely relevant.

Research has consistently shown that significant, sustained weight loss reduces circulating inflammatory markers including C-reactive protein (CRP), IL-6, and TNF-alpha. As visceral fat decreases, the steady-state pro-inflammatory signaling from adipose tissue also decreases. Immune cells that were chronically activated by adipokine signaling regain some of their normal responsiveness. Blood sugar control improves, which independently benefits immune cell function. Cardiovascular risk decreases, which affects tissue perfusion and immune cell trafficking.

For people managing their weight with GLP-1 receptor agonists like compounded semaglutide or tirzepatide, these metabolic improvements begin early in treatment and accumulate with continued therapy. The degree of weight loss achieved with GLP-1 medications is clinically substantial, which means the downstream immune benefits from weight reduction are likely more meaningful than those seen with modest weight loss interventions.

The honest picture is that both mechanisms probably contribute to the infection outcome signals seen in observational research: direct GLP-1 receptor effects on immune cells, and the immune improvements that follow from meaningful weight reduction.

---

What This Research Does Not Prove

Several important limitations apply to everything discussed here.

First, most of this evidence comes from observational studies of patients who are primarily managing diabetes or obesity. These patients may differ from the broader population seeking weight management in ways that affect both their immune baselines and their infection risks.

Second, many of the mechanistic studies on GLP-1 and immune function are preclinical, conducted in cell cultures or animal models. These findings inform the biological plausibility of a direct immunomodulatory effect, but they do not establish that GLP-1 receptor agonists produce equivalent immune effects in humans.

Third, the research does not support the conclusion that GLP-1 medications are protective against any specific infection. People on GLP-1 therapy still need standard preventive care, including vaccinations, infection surveillance, and appropriate treatment when infections occur.

Finally, it is worth noting that some GLP-1 side effects may have indirect immune implications. Nausea and reduced appetite can potentially affect nutritional status over time, and maintaining adequate protein and micronutrient intake during GLP-1 therapy is an important consideration for overall immune function. Your provider can help you understand how to support your nutrition during treatment.

---

Practical Context for People on GLP-1 Therapy

If you are using a GLP-1 program for weight management, the immune-related research here offers context rather than clinical guidance. Here is how to think about it.

The metabolic improvements that come with successful GLP-1 treatment, including meaningful weight reduction, better blood sugar control, and reduced systemic inflammation, are likely to have real consequences for how your body responds to infections. This is one more area where the science of obesity medicine intersects with general health in ways that go beyond the number on the scale.

At the same time, GLP-1 medications are not a substitute for conventional preventive care. Staying current on recommended vaccines, maintaining good nutrition during treatment, and working with your provider team to monitor your overall health remain essential.

The anti-inflammatory and immune-related dimensions of GLP-1 research are part of a broader picture: these medications affect far more biological systems than their original indication suggested. Understanding that picture helps you have more informed conversations with your care team.

---

Summary: What the Current Evidence Suggests

The research on GLP-1 receptor agonists and immune function points in a consistent direction, while remaining early in maturity.

Obesity impairs immune function through chronic low-grade inflammation and immune cell exhaustion. GLP-1 receptors are expressed on immune cells, and receptor activation has been shown in preclinical models to reduce pro-inflammatory signaling. Observational data from COVID-19 studies suggests that GLP-1 receptor agonist users experienced different outcomes compared to other medication classes. Emerging research in sepsis and critical illness is exploring direct therapeutic applications. And the metabolic improvements from significant weight loss, which GLP-1 therapy can achieve, bring their own immune benefits.

What this research does not yet establish: that GLP-1 medications should be prescribed for immune purposes, that they confer protection against any specific infection, or that these findings will hold in randomized controlled trials designed specifically to test immune outcomes.

This is a rapidly evolving area of medicine. The coming years will clarify how much of the immune signal in the observational data reflects direct GLP-1 receptor effects versus the metabolic benefits of weight loss. For now, the evidence adds to the accumulating picture of GLP-1 receptor agonists as compounds whose biological effects extend well beyond blood sugar and appetite.

---

*This article is for educational and informational purposes only. Compounded semaglutide and tirzepatide are not FDA-approved. Clinical research cited here involved FDA-approved formulations or observational populations. GLP-1 medications are not a treatment for COVID-19 or any infection. Consult your licensed healthcare provider before starting or adjusting any medication. Care through Prescriva is provided by independently licensed healthcare providers, not by Prescriva LLC, doing business as Prescriva, which operates as a management services organization.*

---

References

1. Valentino TR, et al. The role of autoantibodies in bridging obesity, aging, and immunosenescence. *Immun Ageing*. 2024 Nov 30. [PMID 39616399](https://pubmed.ncbi.nlm.nih.gov/39616399/)
2. Longmore DK, et al. Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis. *Diabetes Care*. 2021 Jun. [PMID 33858854](https://pubmed.ncbi.nlm.nih.gov/33858854/)
3. Bajic Z, et al. Glucagon-like peptide 1 receptor agonists: anti-inflammatory effects in cardiovascular diseases. *Can J Physiol Pharmacol*. 2026 Jan. [PMID 42132521](https://pubmed.ncbi.nlm.nih.gov/42132521/)
4. Thompson W, et al. Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study. *BMJ Open Diabetes Res Care*. 2025 Aug. [PMID 40780839](https://pubmed.ncbi.nlm.nih.gov/40780839/)
5. Song ZH, et al. The Effect of Antihyperglycemic Medications on COVID-19: A Meta-analysis and Systematic Review from Observational Studies. *Ther Innov Regul Sci*. 2024 Jul. [PMID 38683419](https://pubmed.ncbi.nlm.nih.gov/38683419/)
6. Tomy N, et al. The Potential of Using Glucagon-Like Peptide-1 Receptor Agonists in Sepsis. *Cardiol Rev*. 2025 Aug. [PMID 40745623](https://pubmed.ncbi.nlm.nih.gov/40745623/)